Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the Maxim Group LLC and M Vest LLC Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The presentation will cover the company's rapid PCR diagnostics platform supporting COVID-19 testing to help normalize daily routines. For registration details, visit the conference link. An archived version of the presentation will be available on the Co-Diagnostics website post-event. The company focuses on developing advanced molecular diagnostic tests using its proprietary technology.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced that CEO Dwight Egan will present at the 2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference on March 11-12, 2021. Egan's presentation, scheduled for 12:10 pm ET on March 11, will cover the company's rapid PCR point-of-care and at-home testing platform for COVID-19 and other infectious diseases. This platform utilizes Co-Diagnostics' proprietary technology for enhanced testing efficiency. Attendees can register for the conference via the provided link.
Co-Diagnostics, Inc. (NASDAQ-CM: CODX) announced that CEO Dwight Egan will present at the 2021 H.C. Wainwright & Co. Global Life Sciences Conference, held virtually on March 9-10, 2021. Participants can register for the conference and access an archived version of the presentation on the company's website. Co-Diagnostics develops and markets advanced molecular diagnostic technology, focusing on tests that analyze nucleic acids. The company emphasizes its ongoing expansion and the potential for increased sales and distribution of its innovative liquid biopsy tests.
Co-Diagnostics, Inc. (Nasdaq: CODX) introduced a new PCR diagnostic testing platform for Covid-19 suitable for businesses, schools, and homes. This compact device employs a Direct Saliva extraction-free protocol to provide rapid results via a smartphone app. Designed for accessibility, this platform aims to augment traditional testing methods, allowing for affordable, accurate surveillance. Co-Diagnostics plans to expand the device's capabilities to include testing for other pathogens, with regulatory submission expected later this year.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its partner, Clinical Reference Laboratory, is offering an FDA-authorized Rapid Response COVID-19 Saliva Test through Walgreens Find Care. This non-invasive service allows consumers to undergo PCR-based COVID-19 testing at home using Co-Diagnostics' CoPrimer technology. The saliva samples are tested for SARS-CoV-2 via CRL's RT-PCR test. CEO Dwight Egan highlighted the importance of expanding accessibility to quality diagnostic solutions through at-home collection devices.
On February 24, 2021, Clinical Reference Laboratory (CRL) partnered with Walgreens to launch the FDA-authorized Rapid Response COVID-19 Saliva Test via Walgreens Find Care. This non-invasive test allows users to self-collect samples at home, boasting 100% sensitivity and specificity. Priced at $119, results are typically available within 24-48 hours. Walgreens aims to enhance access to COVID-19 testing, integrating it into their digital health platform. CRL has distributed over 500,000 tests, affirming its commitment to convenient and reliable testing solutions.
Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Brian Brown as Chief Financial Officer and Dr. Jesse Montgomery as Chief Scientific Officer, as part of its strategy for growth. Mr. Brown brings extensive financial experience, while Dr. Montgomery has previously served as Senior VP of Biochemistry. The company aims to enhance its financial department and scientific initiatives following significant growth and anticipates further progress in molecular diagnostics. Former CFO Reed Benson stays on as general counsel, and Dr. Brent Satterfield leads the Scientific Advisory Board.
Co-Diagnostics (Nasdaq: CODX) announced its participation in the 28th Annual International Molecular Medicine Tri-Conference, presenting its innovative Logix Smart SARS-CoV-2 DS (Direct Saliva) testing kit for COVID-19. The virtual presentation is scheduled for February 16, 2021, at 4:30 pm EST, including a test demonstration and a Q&A panel. The company aims to improve testing throughput and accessibility through this technology, which has been submitted for Emergency Use Authorization by the FDA. The test detects all known SARS-CoV-2 variants, enhancing global testing capabilities.
Co-Diagnostics (Nasdaq-CM: CODX) announced completion of its FDA submission for Emergency Use Authorization for its Logix Smart™ SARS-CoV-2 DS test, which detects COVID-19 in saliva samples without RNA extraction. This innovation aims to reduce testing costs and processing times, enhancing throughput in high-volume labs. CEO Dwight Egan emphasized the test's potential for quicker and affordable diagnostics, meeting rising global demand amidst the pandemic. The company continues to advance its proprietary technology to improve molecular diagnostics further.
Co-Diagnostics (Nasdaq-CM: CODX) will participate in the H.C. Wainwright & Co. BioConnect 2021 Conference from January 11-14, 2021. CEO Dwight Egan will join a panel hosted by former FDA Commissioner Scott Gottlieb on January 12 at 12:00 pm ET. Registration for the panel is available online. Additionally, Egan will engage in a fireside chat with Yi Chen, which will be accessible on-demand starting January 11 at 6:00 am ET through the Co-Diagnostics website.
The company specializes in molecular diagnostics, focusing on innovative tests for nucleic acid detection.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
